The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Reply to the letter to the editor

Reply to the letter to the editor “Impella device use in high-risk PCI”

EuroIntervention 2019;15:732-732. DOI: 10.4244/EIJ-D-19-00279R

1. Section of Interventional Cardiology, MedStar Washington Hospital Center, Washington, DC, USA


We appreciate Chhabra and colleagues’ correspondence1 regarding our recent report on the adverse events associated with the Impella® (Abiomed, Danvers, MA, USA) devices as identified in the Manufacturer and User Facility Device Experience (MAUDE) database2. We agree that the data to support the routine use of mechanical circulatory support (MCS) devices in the setting of high-risk percutaneous coronary intervention (PCI) are limited. As highlighted by the authors, lessons learned from the randomised pivotal BCIS-1 trial brought the intra-aortic balloon pump (IABP) train to a grinding halt1. While the benefits and efficacy of the Impella in the PROTECT ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Impact of implant depth on hydrodynamic function with the ALLEGRA transcatheter heart valve following valve-in-valve intervention